secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001999371-25-014108
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix plans Phase 2 trial of TNX-2900 for Prader-Willi syndrome in 2026
-----------------------------------------------------------------------

- TNX-2900 (intranasal magnesium-potentiated oxytocin) to enter Phase 2 in children ages 8-17.5 with PWS, starting 2026.
- FDA cleared IND; Orphan Drug and Rare Pediatric Disease designations; eligible for Priority Review Voucher upon approval.
- Phase 2 trial is randomized, double-blind, placebo-controlled; 12-week treatment; 3 dose arms vs placebo (1:1:1:1).
- Primary endpoint: change from baseline in Hyperphagia Questionnaire (HQ-CT); secondary: behavior, caregiver burden, quality of life.
- PWS affects 1 in 10,000-30,000 births; average life expectancy <30 years due to hyperphagia-driven obesity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014108/0001999371-25-014108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014108/tnxp-8k_092925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-014108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer